Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

BACKGROUND: Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology (muscarinic receptor antagonist and β(2−)adrenoceptor agonist) molecule in development for chronic obstructive pulmonary disease and asthma. METHODS: These two phase I, randomised, single-blind, multiple-ascending-dose stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Balaguer, Victor, Albayaty, Muna, Jimenez, Eulalia, Wählby-Hamrén, Ulrika, Astbury, Carol, Seoane, Beatriz, Malice, Marie-Pierre, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488005/
https://www.ncbi.nlm.nih.gov/pubmed/32907575
http://dx.doi.org/10.1186/s12931-020-01474-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488005/
https://www.ncbi.nlm.nih.gov/pubmed/32907575
http://dx.doi.org/10.1186/s12931-020-01474-1

Ejemplares similares